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Abstract
Transcranial magnetic stimulation (TMS) is an approved intervention for treatment-resistant depression (TRD), but
current targeting approaches are only partially successful. Our objectives were (1) to examine the feasibility of MRI-
guided TMS in the clinical setting using a recently published surface-based, multimodal parcellation in patients with
TRD who failed standard TMS (sdTMS); (2) to examine the neurobiological mechanisms and clinical outcomes
underlying MRI-guided TMS compared to that of sdTMS. We used parcel-guided TMS (pgTMS) to target the left
dorsolateral prefrontal cortex parcel 46. Resting-state functional connectivity (rsfc) was assessed between parcel 46 and
predefined nodes within the default mode and visual networks, following both pgTMS and sdTMS. All patients (n=
10) who had previously failed sdTMS responded to pgTMS. Alterations in rsfc between frontal, default mode, and visual
networks differed significantly over time between groups. Improvements in symptoms correlated with alterations in
rsfc within each treatment group. The outcome of our study supports the feasibility of pgTMS within the clinical
setting. Future prospective, double-blind studies of pgTMS vs. sdTMS appear warranted.
Introduction
Transcranial magnetic stimulation (TMS) over left
dorsolateral prefrontal cortex (L-DLPFC) is an FDA-
approved treatment for treatment-refractory depression
(TRD), but only partially effective, with response and
remission rates of 41.2% and 35.3%, respectively1,2. Cur-
rent targeting techniques for rTMS rely on distance from
motor cortex (“5-cm rule”). This approach provides only
approximate targeting of L-DLPFC, with no consistent
differentiation among potentially relevant DLPFC sub-
regions. A long-term goal of TMS research is to guide
TMS targeting on a personalized basis, in order to
improve consistency of targeting across individuals.
Nevertheless, optimal methods for targeting remain to be
developed3–5.
Recently, we evaluated resting-state functional con-
nectivity (rsfc) changes pre/post electroconvulsive therapy
(ECT)6, in order to identify specific rTMS targets within
L-DLPFC. Moreover, we applied a prespecified surface-
based multimodal parcellation scheme that divides
DLPFC into 13 distinct subregions (“parcels”), in order to
permit consistent identification across individuals (Sup-
plementary Fig. 1). We observed greatest correlation of
ECT response to changes in rsfc involving two specific
DLPFC parcels—46 and p9-46v—on one part, and brain
regions considered to be involved in the pathophysiology
of depression, including the anterior default mode net-
work (DMN, s32) and ventral visual region (VIS, ventral)
on the other.
Here, we evaluated effects of excitatory (10 Hz) “parcel-
guided” rTMS (pgTMS) targeted at DLPFC(46) using
individualized MRI, relative to effects of standard “5-cm
rule” rTMS (sdTMS). In addition to symptoms, we eval-
uated rsfc changes induced by pgTMS vs. sdTMS, relative
to patterns of change previously observed pre/post ECT.
We hypothesized that pgTMS would show beneficial
effects in TRD individuals who were nonresponsive to
sdTMS, and that these changes would be associated with
differential effects on underlying network connectivities6.
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Methods
Participants
We obtained Hamilton Depression Rating Scale (HDRS)
and resting-state functional MRI (rsfMRI) scans pre/post
rTMS in a group of ten TRD subjects who were non-
responders to sdTMS and who received pgTMS targeted
at parcel 46, and compared both magnitude of change and
rsfc correlates relative to a group of 22 rTMS-naive TRD
subjects given sdTMS (Supplementary Fig. 2). All subjects
met DSM-IV criteria for a major depressive episode
according to the diagnostic assessment by the Structured
Clinical Interview Patient Edition.
The ten subjects studied pre–post pgTMS were drawn
from a pool of clinical patients at different locations, who
did not respond adequately to standard ongoing treat-
ments. All pgTMS treatments were done at the Green-
wich location (ages 18–60). All subjects were right-
handed and without severe medical conditions. The
NYSPI/CUMC and Western Institutional Review Board
approved this study, which was registered online
(clinicaltrials.gov registration NCT02974296). All parti-
cipants provided written informed consent.
Treatment
All treatments were open label and administered using a
NeuroStar Therapy System. sdTMS used standard “5-cm
rule” targeting. pgTMS stimulation locations were deter-
mined using a Brainsight (Rogue Research, Montreal,
Canada) neuronavigation system. All patients completed
36 sessions, with 5×/week for 6 weeks, followed by
3 weeks taper off. TMS was administered at 120% of
motor threshold at a frequency of 10 Hz, for a total of
3000 pulses per session. To obtain preliminary data on
differences between standard vs. individualized targeting,
the same TMS device and treatment protocol were used
in the sdTMS group (as part of routine clinical care) and
the pgTMS group. After completion of TMS treatments
patients received a second rsfMRI scanning followed by
the HDRS-24.
MRI
Anatomical images and rsfMRI were collected using a
GE Discovery MR750 3.0 Tesla full-body MRI. DLPFC,
DMN, and VIS regions, were operationalized respectively
as parcels 46, s32, and the VIS ventral region7. Target
location for pgTMS was determined using vertices within
DLPFC(46) that showed greatest anticorrelation to s32
(Supplementary Fig. 3b).
Statistics
Preplanned analyses focused on mixed effect regression
models to test whether change in rsfc pre/post both
sdTMS and pgTMS differs by treatment group.
Association between change in HDRS and that of each
rsfc was measured using linear regression. Group differ-
ence in the association was tested by adding the interac-
tion term between change in rsfc and treatment group.
Fisher’s z-transform was applied to individual rsfc maps
before group level analyses; corrected p-values using
FDR8 controlled multiple comparison correction were
computed (see Supplementary Methods for further
details). Bartlett’s test was performed to test variance
homogeneity across groups. Wherever equal variance
hypothesis was rejected, we refit the model allowing dif-
ferent variance by group.
Results
Symptoms
Of the ten patients treated with pgTMS following
nonresponse to sdTMS, all (100%) showed a significant
response, with 50% showing full remission. By contrast,
46% of patients treated with sdTMS (10 out of 22) showed
a significant response, with 18% remission. The difference
in mean symptoms change (64 ± 15% vs. 28 ± 27%, t=
−3.99, p < 0.001) and response rate (χ²= 6.56, p= 0.004)
between groups was statistically reliable (Fig. 1a).
rsfc
No baseline differences in rsfc were found between the
groups (Supplementary Table 1). Connectivity between
DLPFC(46) and DMN(s32) (Fig. 1b), or between DMN
(s32) and VIS(ventral) (Fig. 2a) differed significantly over
time between groups in post–pre changes (Figs. 1c and 2b,
Supplementary Table 2). There were also differences in
connectivity by group (Supplementary Table 3). We found
increased negative correlation between DLPFC(46) and
DMN(s32) (Fig. 1c), and between DMN(s32) and VIS
(ventral) (Fig. 2b), following sdTMS.
By contrast, increased positive correlation between
DLPFC(46) and DMN(s32) (Fig. 1c), and between DMN
(s32) and VIS(ventral) (Fig. 2b) followed pgTMS. The
correlation between change in depression scores (HDRS)
and rsFC also differed by group (Supplementary Table
4.1). Specifically, individuals in the sdTMS group showed
greater negative connectivity associated with improvement
in depression scores (Figs. 1d and 2c, Supplementary Table
4.2), with a pattern similar to that previously observed pre/
post ECT treatment6 (Fig. 2d, f), while the opposite pattern
was found in the pgTMS (Fig. 2e). Results stayed very
similarly (Supplementary Table 5.1–5.4) after potential
outliers were removed, and still significant after control-
ling for multiple comparison correction.
Similar results were obtained in both groups for other
VIS regions, including dorsal, MTC, and early (Supple-
mentary Results). Moreover, results remained significant
following multiple comparison correction.
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Relative location
For all sdTMS subjects, we approximated the likely
target location by plotting the MNI coordinates −41, 16,
and 54 of the average 5-cm rule9 unto the Glasser par-
cellation scheme10. Targets mapped primarily to area 8Av
(Supplementary Fig. 3a), known to be part of the DMN.
Responders and nonresponders to sdTMS were not
notably different in estimated target location. For pgTMS
subjects, targets fell within the most anterior/ventral
region of DLPFC(46) (Supplementary Fig. 3b); known to
be part of the fronto-parietal network.
Discussion
Limitations of the “5-cm rule” for guiding sdTMS are
well understood5. Nevertheless, no alternative targeting
strategies have attracted widespread use. Here, we take
advantage of recent advances in surface-based multimodal
parcellation of cortex10, as well as our recent findings of
pre/post changes in rsfc following successful ECT6 to
refine targeting for rTMS in depression. As predicted, we
observed significant improvement following pgTMS in
individuals who were nonresponsive to sdTMS. More-
over, we observed opposite patterns of rsfc change fol-
lowing pgTMS vs. sdTMS, reinforcing the importance of
precise target localization for rTMS stimulation.
DLPFC(46) falls broadly within a region that is antic-
orrelated with subgenual anterior cingulate cortex
(sgACC) (Supplementary Fig. 1b). Our findings, therefore,
are broadly consistent with a large body of work sug-
gesting that optimal targets for rTMS fall broadly within
Fig. 1 Response rate and change between DLPFC(46) and DMN(s32) connectivity. a Difference in response rate between groups (sdTMS vs.
pgTMS). b Brain images display the contrast pgTMS vs. sdTMS of the parcellation-based connectome between left DLPFC(46) (lateral view) used as
seed and left DMN(s32) (medial view), both highlighted with black arrows; colors represent parcels with increased negative (blue violet) or increased
positive (red yellow) correlation with left DLPFC(46) in pgTMS vs. sdTMS. c Bar plot with rsfc change difference between left DLPFC(46) and left DMN
(s32) by group, and of each group. d Correlation plot with group difference in the association between change in HDRS and change in rsfc. Corrected
p-values using FDR8 controlled multiple comparison correction are displayed.
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sgACC “anticorrelated” region of L-DLPFC9,11. Never-
theless, operationalizing this approach using personalized
rsfc measures has proven challenging, in part because of
long acquisition times needed to get stable, single-subject
rsfc solutions3,12–14.
Here, we demonstrate that utilization of a surface-based
parcellation scheme gives unexpectedly superior results
vs. sdTMS. In our recent ECT study, we observed greater
connectivity changes in a circuit involving L-DLPFC(46),
s32, and VIS cortex than between L-DLPFC(46) and
sgACC(25), suggesting potentially greater importance of
these connections vs. the more traditionally studied
connections to sgACC. Our present pre/post results fur-
ther support the importance of these connections. How-
ever, we cannot discount the potential role of sgACC in
the present study, since the surface-based parcellation
used for analyses separates areas 25 and s32 (or subgenual
32), a difference that might be lost in voxel-based defi-
nitions of sgACC (or BA25). Our findings also suggest
that s32 may serve as an appropriate target for deep brain
stimulation, along with area 25.
In our study, all subjects first received the FDA-
approved “5-cm rule” treatment (sdTMS) before being
entered into experimental treatment. In our group of ten
subjects who did not respond to sdTMS, all subjects who
received pgTMS responded to treatment as defined based
on ≥25% reduction in symptoms, and 50% (5/10) obtained
remission. Both mean symptom change and % of subjects
showing treatment response were significantly greater for
pgTMS than for a parallel group of subjects, who received
sdTMS for the first time, as well as those expected from
rTMS meta-analyses15.
In addition to symptom change, we also observed rsfc
changes within the predefined DLPFC, DMN, and VIS
circuit, suggesting objective physiological effects. Sur-
prisingly, we observed an opposite pattern of rsfc change
in the sdTMS and pgTMS groups. sdTMS produced
changes similar to those observed pre/post ECT, albeit
weaker, suggesting a convergent mechanism of effect. By
contrast, pgTMS produced an opposite pattern of change.
Interactions between DLPFC(46), DMN(s32), and VIS
(ventral) are critical for normal goal-directed VIS activ-
ity16, and is consistent with spatio-temporal dynamics of
interactions between emotional stimulus and task-driven
attention17,18. In particular, the simultaneous increase in
DLPFC–DMN and DMN–VIS connectivity in the pgTMS
Fig. 2 Change between DMN(s32) and VIS(ventral) connectivity. a Brain images display the contrast pgTMS vs. sdTMS of the parcellation-based
connectome between left DMN(s32) (medial view) used as seed (highlighted with a black arrow) and bilateral VIS(ventral) (lateral and medial views),
all parcels within the ventral region are highlighted in black; colors represent parcels with increased negative (blue violet) or increased positive (red
yellow) correlation with left DMN(s32) in pgTMS vs. sdTMS. b Bar plot with rsfc change difference between left DMN(s32) and bilateral VIS(ventral) by
group, and of each group. c Correlation plot with group difference in the association between change in HDRS and change in rsfc. Corrected p-
values using FDR8 controlled multiple comparison correction are displayed. (d–f) Schematic representation of rsfc structure after sdTMS (d), pgTMS
(e), or ECT (f); colored straight lines show significant connections, with positive (+) or negative (−) rsfc correlation; black dot lines show absence of
significant connections.
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group might underlie the mechanism by which frontal
structures regulate attention and emotion influences on
VIS cortex.
A mechanistic explanation of this interaction could be
that both emotional salience feedback from the DMN and
top-down signaling from DLPFC regions synergistically
increase processing in the VIS cortex17. Long-range
cortico–cortical projections might act through local
microcircuits to exert spatially specific top-down mod-
ulation of sensory processing19. Restoration of these small
local circuits might be crucial for the development of
long-range cortico–cortical projections to exert specific
top-down modulation of attention and emotion influ-
ences on sensory processing.
The present results suggest a dysfunctional pattern
associated with depression that can be modulated bidir-
ectionally (top-down/bottom-up), depending upon the
precise location of the rTMS target. The present study
reinforces first that small shifts in target location within
DLPFC may produce large differences in outcome, and
that alterations in rsfc patterns may be helpful both in
selection of subjects and monitoring of response20,21.
The present study differs from prior studies that have
used structurally22 or functionally23–25 guided rTMS in
that it uses surface—rather than volume-guided targeting
—and considers rsfc to DMN and VIS, as well as sgACC
based upon our recent findings. Surface-based targeting
provides approximately threefold greater spatial localiza-
tion than does traditional volumetric targeting26. More-
over, use of a predesignated parcellation scheme greatly
reduces data dimensionality and permits greater com-
parability of results across studies. In the present study,
we further refined targeting on an individual basis using
rsfc to DMN, which implicated ventral regions of area 46
(Supplementary Fig. 3b). Nevertheless, dispersion of the
target was small across subjects, suggesting that targeting
might be accomplished using structural MRI alone.
Patients receiving sdTMS in this study showed response and
remission rates similar to those previously reported5. An
unanswered question is whether the greater treatment
response and higher remission rates with pgTMS relative to
both, sdTMS subjects and prior literature, are because the
subjects were specifically chosen based on nonresponsiveness
to sdTMS, or whether similar effects might be observed even
in unselected TRD patients. Also, because pgTMS was used as
a continuation to sdTMS, patients in the pgTMS received
longer total treatment than those in the sdTMS group. Prior
continuation studies have suggested response rates of 11–40%
with continued high-frequency stimulation to L-DLPFC27,28,
but higher response rates following a change in either the
target or the device28,29.
Cole et al.25 have recently published a similar study
using a much more aggressive stimulation TMS protocol.
Their study was also small and open label, and also
showed extremely high response rates (>90%) in a sample
of unselected TRD patients, including a subsample of
nonresponders to TMS. However, some differences
between the studies require further discussion. First, we
used targeting based upon a structural atlas, rather than
mapping rsFC patterns for each person. The use of a
structural atlas reduces the computational burden needed
to calculate rsFC patterns for individual subjects, and thus
may be more clinically applicable. Second, we used a
standard FDA-approved stimulation approach (10 Hz
stimulation, 3000 pulses/session, 30 sessions) to better
match ongoing TMS treatment. Nevertheless, our pro-
posed targeting approach could potentially be used in
future intensive stimulation studies.
The present study is limited by the small sample size,
open design, and sequential treatment. Nevertheless, it
demonstrates feasibility of the personalized surface and
parcel-based approach for guiding TMS treatment, as well
as the use of pre/post rsfc imaging to analyze underlying
therapeutic mechanisms. Future parallel-group studies are
needed to directly compare efficacy of pgTMS vs. sdTMS,
as well as feasibility of the parcel-guided approach within
larger treatment samples.
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